Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the reporting period ending April 30, 2025. The report serves to distribute a press release dated April 30, 2025, to U.S. investors pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not available in this document.
Material Changes
The filing text does not provide information regarding material changes compared to prior periods, as the content is limited to the cover page and exhibit index.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the provided text. The filing references a press release (Exhibit 99.1) which likely contains these details, but the text of the press release is not included in the input.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) referenced in the filing for specific operational or financial updates.
- Verify the content of the press release for any new clinical trial data, regulatory milestones, or partnership announcements typical for Innate Pharma S.A.
- Confirm the date and content of the press release against the company's official investor relations website.